دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.04.012
Volume 83, Issue 6, June 2023, Pages e145-e155
Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
Abirramy Varatharajan a,*, Timothe �e Olivier b , Vinay Prasad
doi : 10.1016/j.eururo.2023.01.024
Volume 83, Issue 6, June 2023, Pages 481-483
Urology for Social Responsibility: Choosing a Lane
Manoj Monga
doi : 10.1016/j.eururo.2023.02.019
Volume 83, Issue 6, June 2023, Pages 484-485
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
Noah M. Hahn a,b,c,*, Michael A. O’Donnell d , Jason A. Efstathiou e,f , Marianna Zahurak a , Gary L. Rosner a , Jeff Smith g , Max R. Kates a,b,c , Trinity J. Bivalacqua a,b,c,h , Phuoc T. Tran a,b,c,i,j , Daniel Y. Song a,b,c,i , Alex S. Baras a,b,c,k , Andres Matoso a,b,c,k , Woonyoung Choi a,b,c , Kellie N. Smith a,b,l , Drew M. Pardoll a,b,l , Luigi Marchionni a,b,m,n , Bridget McGuire a,b,c , Mary Grace Phelan a,b,c , Burles A. Johnson III a,b,c , Tanya O’Neal a , David J. McConkey a,b,c , Tracy L. Rose o,p , Marc Bjurlin o,q , Emerson A. Lim r,s , Charles G. Drake r,t , James M. McKiernan r,u , Israel Deutsch r,v , Christopher B. Anderson r,u , Donald L. Lamm w , Daniel M. Geynisman x , Elizabeth R. Plimack x , Mark A. Hallman y , Eric M. Horwitz y , Essel Al-Saleem z , David Y.T. Chen aa , Richard E. Greenberg aa , Alexander Kutikov aa , Gordon Guo bb,cc , Timothy A. Masterson dd , Nabil Adra ee , Hristos Z. Kaimakliotis
doi : 10.1016/j.eururo.2023.01.017
Volume 83, Issue 6, June 2023, Pages 486-494
ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non–muscle-invasive Bladder Cancer
Priyamvada Maitre a , Vijay Sangar b , Ananya Choudhury
doi : 10.1016/j.eururo.2023.02.018
Volume 83, Issue 6, June 2023, Pages 495-496
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Wei Shen Tan a,b,*, Aaron Prendergast c , Charlotte Ackerman c , Yathushan Yogeswaran c , Joanne Cresswell d , Paramananthan Mariappan e , Jaspal Phull f , Paul Hunter-Campbell g , Henry Lazarowicz h , Vibhash Mishra i , Abhay Rane j , Melissa Davies k , Hazel Warburton l , Peter Cooke m , Hugh Mostafid n , Daniel Wilby o , Robert Mills p , Rami Issa q , John D. Kelly
doi : 10.1016/j.eururo.2022.08.003
Volume 83, Issue 6, June 2023, Pages 497-504
Results from HIVEC-II for Intermediate-risk Non–muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
Clara Cerrato a , Morgan Roupret b , Maria Carmen Mir
doi : 10.1016/j.eururo.2023.03.004
Volume 83, Issue 6, June 2023, Pages 505-507
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
̈tan Devos a,b , Lorenzo Tosco a , Marcella Baldewijns c , Thomas Gevaert a , Karolien Goffin d , Valentin Petit e , Cindy Mai e , Annouschka Laenen f , Yannic Raskin a , Carl Van Haute a , Lieven Goeman b , Gert De Meerleer g , Charlien Berghen g , Wout Devlies a,h , Frank Claessens h , Hendrik Van Poppel a , Wouter Everaerts a,b , Steven Joniau
doi : 10.1016/j.eururo.2022.09.009
Volume 83, Issue 6, June 2023, Pages 508-518
High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence and metastatic progression following radical prostatectomy (RP).
Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full?
Bruce Montgomery a,b,*, Elahe A. Mostaghel
doi : 10.1016/j.eururo.2023.01.021
Volume 83, Issue 6, June 2023, Pages 519-520
Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer
Laura Bukavina a,b , Amy N. Luckenbaugh b , Michael S. Hofman c,d , Tom Hope e , Sophia C. Kamran f , Declan G. Murphy d,g , Kosj Yamoah h , Piet Ost
doi : 10.1016/j.eururo.2022.10.024
Volume 83, Issue 6, June 2023, Pages 521-533
Prostate-specific membrane antigen (PSMA) is a promising molecular target for prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to PCA in the primary and recurrent settings.
Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis
Jean-Nicolas Cornu a,*, Paul Zantek b , Glyn Burtt b , Chris Martin c , Alison Martin c , Cassandra Springate c , Bilal Chughtai
doi : 10.1016/j.eururo.2023.02.028
Volume 83, Issue 6, June 2023, Pages 534-547
Minimally invasive surgical therapies for male lower urinary tract symptoms secondary to benign prostatic obstruction were developed to be safer and more tolerable than standard ablative techniques. These treatments have not been compared with each other in a randomised fashion, and for some treatments, there are no trials against a reference technique.
European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update☆
Oscar R. Brouwer a,*, Maarten Albersen b , Arie Parnham c , Chris Protzel d , Curtis A. Pettaway e , Benjamin Ayres f , Tiago Antunes-Lopes g , Lenka Barreto h , Riccardo Campi i , Juanita Crook j , Sergio Ferna �ndez-Pello k , Isabella Greco l , Michiel S. van der Heijden m , Peter A.S. Johnstone n , Mithun Kailavasan o , Kenneth Manzie p , Jack David Marcus q , Andrea Necchi r , Pedro Oliveira s,t,u , John Osborne p , Lance C. Pagliaro v , Herney A. Garcia-Perdomo w , R. Bryan Rumble x , Ashwin Sachdeva y , Vasileios I. Sakalis z , �ukasz Zapala aa , Diego F. Sa �nchez Martı �nez bb , Philippe E. Spiess cc , Scott T. Tagawa dd
doi : 10.1016/j.eururo.2023.02.027
Volume 83, Issue 6, June 2023, Pages 548-560
Penile cancer is a rare disease but has a significant impact on quality of life. Its incidence is increasing, so it is important to include new and relevant evidence in clinical practice guidelines.
A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial
Gabriela Ilie a,b,c,*, Ricardo Rendon a , Ross Mason a , Cody MacDonald b , Michael J. Kucharczyk c , Nikhilesh Patil c , David Bowes c , Greg Bailly a , David Bell a , Joseph Lawen a , Michael Ha c , Derek Wilke c , Peter Massaro a , Jeffery Zahavich d , George Kephart b , Robert David Harold Rutledge
doi : 10.1016/j.eururo.2023.02.009
Volume 83, Issue 6, June 2023, Pages 561-570
Although survival rates for newly diagnosed prostate cancer patients are very high, most of them will likely suffer significant treatment-related side effects, depression, or anxiety, affecting their quality of life.
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial
Soumyajit Roy a,y,*, Yilun Sun b,y, Scott C. Morgan c,y, Christopher J.D. Wallis d,y, Kevin King a , Yu M. Zhou a , Leah A. D’souza a , Omar Azem a , Adrianna E. Cueto-Marquez a , Nathaniel B. Camden a , Daniel E. Spratt e,à , Amar U. Kishan f,à , Fred Saad g,à , Shawn Malone
doi : 10.1016/j.eururo.2023.02.017
Volume 83, Issue 6, June 2023, Pages 571-579
Men with localized prostate cancer are often treated with local therapy (LT). However, a proportion of these patients will eventually develop recurrence and progression requiring systemic therapy. Whether primary LT affects the response to this subsequent systemic treatment is unclear.
Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Gontero Paolo
doi : 10.1016/j.eururo.2023.01.008
Volume 83, Issue 6, June 2023, Page 580
Re: IL-15 Superagonist NAI in BCG-Unresponsive Non–muscle-invasive Bladder Cancer
Jonathan Suderman * Marie-Pier St-Laurent Peter C. Black
doi : 10.1016/j.eururo.2023.01.009
Volume 83, Issue 6, June 2023, Page 581
Re: Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial
Marco Moschini * Francesco Montorsi
doi : 10.1016/j.eururo.2023.01.027
Volume 83, Issue 6, June 2023, Page 582
Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
Alexander P. Kenigsberg a,* Michael Ahdoot b Baris Turkbey c Peter A. Pinto
doi : 10.1016/j.eururo.2023.02.022
Volume 83, Issue 6, June 2023, Pages 582-583
Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology
Rui Bernardino * Neil Fleshner
doi : 10.1016/j.eururo.2023.01.028
Volume 83, Issue 6, June 2023, Pages 583-584
Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
Timothée Olivier a,* Petros Tsantoulis a Vinay Prasad
doi : 10.1016/j.eururo.2023.01.026
Volume 83, Issue 6, June 2023, Pages 584-585
Re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021
Kirti Singh * Swarnendu Mandal Manoj Kumar Das Prasant Nayak Sambit Tripathy
doi : 10.1016/j.eururo.2022.12.040
Volume 83, Issue 6, June 2023, Page e156
Reply to Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak, and Sambit Tripathy’s Letter to the Editor re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021
Yue Che Andreas Hiester * Peter Albers
doi : 10.1016/j.eururo.2023.02.012
Volume 83, Issue 6, June 2023, Page e157
Re: NIHR Global Research Health Unit on Global Surgery. Routine Sterile Glove and Instrument Change at the Time of Abdominal Wound Closure to Prevent Surgical Site Infection (ChEETAh): A Pragmatic, Cluster-randomised Trial in Seven Low-income and Middle-income Countries. Lancet 2022;400:1767–76
Malte W. Vetterlein a Quoc-Dien Trinh b,c Thomas Seisen
doi : 10.1016/j.eururo.2023.02.014
Volume 83, Issue 6, June 2023, Page e158
Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313–7
Chunliang Cheng Jiao Hu Jinbo Chen
doi : 10.1016/j.eururo.2023.02.029
Volume 83, Issue 6, June 2023, Pages e159-e160
Re: Peter L. Sunaryo, Philip C. May, Sarah K. Holt, Matthew D. Sorensen, Robert M. Sweet, Jonathan D. Harper. Ureteral Strictures Following Ureteroscopy for Kidney Stone Disease: A Population-based Assessment. J Urol 2022;208:1268–75
Guido Giusti Silvia Proietti * Franco Gaboardi
doi : 10.1016/j.eururo.2023.01.030
Volume 83, Issue 6, June 2023, Pages e161-e162
Corrigendum to “Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre� [Eur Urol 2022;82(5):543–550]
Peng Xu a,1, Chunxiao Chen a,1, Binshen Chen a , Enguang Bi a,b , Wei Du a , Ning Jiang a , Zhe Liu a , Hekui Lan c , Manming Cao d , Yazhen Liu a , Jingwen Huang a , Haiyan Shen a , Cunrong Liu a , Chunxiao Liu a,*, Abai Xu
doi : 10.1016/j.eururo.2023.02.015
Volume 83, Issue 6, June 2023, Pages e163-e164
Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer� [Eur Urol 2023;83:313–17]
Alberto Gil-Jimenez a,b,1, Jeroen van Dorp a,1, Alberto Contreras-Sanz c , Kristan van der Vos a , Daniel J. Vis a,b , Linde Braaf d , Annegien Broeks d , Ron Kerkhoven e , Kim E.M. van Kessel f , Marı �a Jose � Ribal g , Antonio Alcaraz g , Lodewyk F.A. Wessels a,b,h , Roland Seiler i,j , Jonathan L. Wright k , Lourdes Mengual g , Joost Boormans f , Bas W.G. van Rhijn l,m , Peter C. Black c , Michiel S. van der Heijden
doi : 10.1016/j.eururo.2023.03.002
Volume 83, Issue 6, June 2023, Page e165
Corrigendum to “Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma� [Eur Urol 2023]
Matthew S. Ernst a , Vishal Navani a , J. Connor Wells a , Frede Donskov b , Naveen Basappa c , Chris Labaki d , Sumanta K. Pal e , Luis Meza e , Lori A. Wood f , D. Scott Ernst g , Bernadett Szabados h , Rana R. McKay i , Francis Parnis j , Cristina Suarez k , Takeshi Yuasa l , Aly-Khan Lalani m , Ajjai Alva n , Georg A. Bjarnason o , Toni K. Choueiri d , Daniel Y.C. Heng
doi : 10.1016/j.eururo.2023.03.003
Volume 83, Issue 6, June 2023, Pages e166-e167
Erratum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer� [Eur Urol 2023;83(3):224–38]
Christina Guo a,b,y, Ines Figueiredo a,y, Bora Gurel a,y, Antje Neeb a , George Seed a , Mateus Crespo a , Suzanne Carreira a , Jan Rekowski a , Lorenzo Buroni a , Jon Welti a , Denisa Bogdan a , Lewis Gallagher a , Adam Sharp a,b , Maria D. Fenor de la Maza a,b , Pasquale Rescigno c , Daniel Westaby a,b , Khobe Chandran a,b , Ruth Riisnaes a , Ana Ferreira a , Susana Miranda a , Bianca Calı` d , Andrea Alimonti d,e,f , Silvia Bressan d,g , Alana H.T. Nguyen h , Michael M. Shen h , Jessica E. Hawley h,i , Aleksandar Obradovic h , Charles G. Drake h,j , Claudia Bertan a , Chloe Baker a , Nina Tunariu a,b , Wei Yuan a , Johann S. de Bono
doi : 10.1016/j.eururo.2023.03.005
Volume 83, Issue 6, June 2023, Pages e168-e169
Erratum to “Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy� [Eur Urol 2022;81(5):446–55]
Qing Cheng a,b,*, William Butler c , Yinglu Zhou c , Hong Zhang c , Lu Tang c , Kathryn Perkinson c , Xufeng Chen c , Xiaoyin ‘‘Sara’’ Jiang b,c , Shannon J. McCall b,c , Brant A. Inman a,b,*, Jiaoti Huang
doi : 10.1016/j.eururo.2023.03.019
Volume 83, Issue 6, June 2023, Pages e170-e171
Acknowledgement to Reviewers
doi : 10.1016/j.eururo.2023.04.014
Volume 83, Issue 6, June 2023, Pages e175-e177
